ArticleRadiation oncology (London, England)2026
Cisplatin enhances radiation-induced apoptosis in peripheral lymphocytes of cancer patients: in vivo and in vitro findings.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConcurrent cisplatin and radiotherapy frequently cause severe acute hematologic toxicity. This study investigated whether lymphocyte apoptosis, quantified via the γ-H2AX pan-nuclear immunostaining assay, can serve as a reliable biomarker for the acute hematologic side effects of combined chemoradiation.
methodsBlood samples were collected from cancer patients and healthy controls. Lymphocyte apoptosis was evaluated using the γ-H2AX pan-nuclear assay following in vitro and in vivo exposure to cisplatin and ionizing radiation (IR). In PBMCs, γ-H2AX results strongly correlated with conventional caspase-3 (r = 0.9736) and annexin V (r = 0.9780) apoptosis assays. Additionally, in vitro experiments assessed how phytohemagglutinin-L (PHA-L)-induced lymphocyte proliferation influences the combined effects of cisplatin and IR on apoptosis, alongside the regulatory role of the ATM protein.
resultsIn vitro, cisplatin increased lymphocyte apoptosis asymptotically, plateauing at 10 µg/ml (11.6 ± 5.0%). Combined cisplatin and IR treatment increased apoptosis in a strictly additive manner (radiation effect: p < 0.0001), with no significant synergistic interaction effect between the two modalities (p = 0.22). The apoptotic effect level of in vivo cisplatin administration did not differ significantly from the maximum effect observed following a 1-hour in vitro exposure to high cisplatin concentrations. In vivo, the additive effect of cisplatin on IR-induced apoptosis peaked up to 3 days post-administration before returning to baseline by day 6. Consistent with these findings, cisplatin and radiation induced a significant, additive increase in apoptosis within PHA-L-stimulated lymphocytes. Inhibition of ATM has no effect on apoptosis following treatment with cisplatin and IR.
conclusionsThe γ-H2AX pan-nuclear assay provides a valid, reliable method for quantifying radiation- and chemotherapy-induced lymphocyte damage. The time-dependent, additive toxicity observed indicates a critical clinical window (up to 3 days post-cisplatin) for maximum hematologic damage, allowing for optimization of treatment schedules. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.